TD Asset Management Inc Grows Stock Position in Natera, Inc. (NASDAQ:NTRA)

TD Asset Management Inc boosted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 18.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,546 shares of the medical research company's stock after purchasing an additional 16,378 shares during the quarter. TD Asset Management Inc owned approximately 0.08% of Natera worth $14,784,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of NTRA. LPL Financial LLC lifted its stake in Natera by 33.7% in the 4th quarter. LPL Financial LLC now owns 80,332 shares of the medical research company's stock worth $12,717,000 after purchasing an additional 20,260 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of Natera by 18.2% in the fourth quarter. Prudential Financial Inc. now owns 18,370 shares of the medical research company's stock valued at $2,683,000 after purchasing an additional 2,824 shares in the last quarter. Blair William & Co. IL bought a new stake in Natera in the fourth quarter worth $426,000. DnB Asset Management AS bought a new stake in shares of Natera in the 4th quarter worth about $235,000. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Natera by 874.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 296,372 shares of the medical research company's stock valued at $46,916,000 after buying an additional 265,948 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 6,111 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $157.10, for a total transaction of $960,038.10. Following the sale, the chief executive officer owned 179,071 shares of the company's stock, valued at $28,132,054.10. This trade represents a 3.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total transaction of $471,210.00. Following the sale, the insider directly owned 133,205 shares in the company, valued at $20,922,509.35. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,936 shares of company stock valued at $7,483,846. Insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NTRA. UBS Group lifted their target price on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Barclays raised their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Evercore ISI assumed coverage on shares of Natera in a research note on Monday. They set an "outperform" rating and a $170.00 target price for the company. Finally, Piper Sandler upped their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and a consensus target price of $183.76.

Natera Trading Up 0.7%

NASDAQ NTRA traded up $0.92 on Friday, hitting $134.58. 1,165,817 shares of the company's stock traded hands, compared to its average volume of 1,202,365. The firm's 50-day moving average price is $157.16 and its two-hundred day moving average price is $155.88. The firm has a market capitalization of $18.38 billion, a PE ratio of -91.55 and a beta of 1.76. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same quarter last year, the business posted ($0.56) EPS. The company's revenue was up 36.5% on a year-over-year basis. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.